CZ83299A3 - Dávková forma [R-(Z)]-alfa-(methoxyimino)-alfa-(1-azabicyklo[2,2,2]okt-3-yl)acetonitril monohydrochloridu s řízeným uvolňováním - Google Patents

Dávková forma [R-(Z)]-alfa-(methoxyimino)-alfa-(1-azabicyklo[2,2,2]okt-3-yl)acetonitril monohydrochloridu s řízeným uvolňováním Download PDF

Info

Publication number
CZ83299A3
CZ83299A3 CZ99832A CZ83299A CZ83299A3 CZ 83299 A3 CZ83299 A3 CZ 83299A3 CZ 99832 A CZ99832 A CZ 99832A CZ 83299 A CZ83299 A CZ 83299A CZ 83299 A3 CZ83299 A3 CZ 83299A3
Authority
CZ
Czechia
Prior art keywords
dosage form
release
coated
polymer
compound
Prior art date
Application number
CZ99832A
Other languages
Czech (cs)
English (en)
Inventor
Susan Marie Milosovich
William Muldoon
James Albert Napper
Laurence Rousseau
Joseph Sauer
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corporation filed Critical Smithkline Beecham Plc
Publication of CZ83299A3 publication Critical patent/CZ83299A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CZ99832A 1996-09-12 1997-09-08 Dávková forma [R-(Z)]-alfa-(methoxyimino)-alfa-(1-azabicyklo[2,2,2]okt-3-yl)acetonitril monohydrochloridu s řízeným uvolňováním CZ83299A3 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition
PCT/GB1997/002418 WO1998010762A2 (en) 1996-09-12 1997-09-08 Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride

Publications (1)

Publication Number Publication Date
CZ83299A3 true CZ83299A3 (cs) 1999-08-11

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ99832A CZ83299A3 (cs) 1996-09-12 1997-09-08 Dávková forma [R-(Z)]-alfa-(methoxyimino)-alfa-(1-azabicyklo[2,2,2]okt-3-yl)acetonitril monohydrochloridu s řízeným uvolňováním

Country Status (22)

Country Link
EP (1) EP0929301A2 (https=)
JP (1) JP2001500150A (https=)
KR (1) KR20000036039A (https=)
CN (2) CN1235544A (https=)
AR (1) AR008176A1 (https=)
AU (1) AU724086B2 (https=)
BR (1) BR9711734A (https=)
CA (1) CA2265661A1 (https=)
CO (1) CO5031291A1 (https=)
CZ (1) CZ83299A3 (https=)
GB (1) GB9619074D0 (https=)
HU (1) HUP9904401A3 (https=)
ID (1) ID19589A (https=)
IL (1) IL128781A0 (https=)
MA (1) MA24359A1 (https=)
NO (1) NO991194D0 (https=)
NZ (1) NZ334268A (https=)
PE (1) PE2499A1 (https=)
PL (1) PL332074A1 (https=)
TR (1) TR199900505T2 (https=)
WO (1) WO1998010762A2 (https=)
ZA (1) ZA978133B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
JP2002506031A (ja) 1998-03-11 2002-02-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 組成物
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2796840B1 (fr) 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
PA8578501A1 (es) 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
JP4808612B2 (ja) 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
ATE339192T1 (de) * 2003-05-14 2006-10-15 Eurand Pharmaceuticals Ltd Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
CN101022788B (zh) 2004-08-13 2010-11-10 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
UA93608C2 (ru) 2004-08-13 2011-02-25 Берингер Ингельхайм Интернациональ Гмбх композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2020214879A1 (en) * 2019-04-19 2020-10-22 Steven Hoffman Sustained release formulations
WO2026013570A1 (en) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. New salt forms of sabcomeline
WO2026013566A1 (en) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. New salt forms of sabcomeline
WO2026013573A1 (en) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. New salt forms of sabcomeline
WO2026013563A1 (en) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. New salt forms of sabcomeline
WO2026018154A1 (en) 2024-07-16 2026-01-22 Syremis Therapeutics Ltd. Combinations of sabcomeline with non-cns penetrant muscarinic antagonists
WO2026018155A1 (en) 2024-07-16 2026-01-22 Syremis Therapeutics Ltd. Combinations of sabcomeline with long-acting non-cns penetrant muscarinic antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48315A1 (en) * 1989-04-13 1998-04-17 Beecham Group Plc Novel compounds
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.

Also Published As

Publication number Publication date
AR008176A1 (es) 1999-12-09
NO991194L (no) 1999-03-11
WO1998010762A2 (en) 1998-03-19
AU724086B2 (en) 2000-09-14
EP0929301A2 (en) 1999-07-21
JP2001500150A (ja) 2001-01-09
CO5031291A1 (es) 2001-04-27
CN1446535A (zh) 2003-10-08
NZ334268A (en) 2000-10-27
PE2499A1 (es) 1999-03-24
ID19589A (id) 1998-07-23
WO1998010762A3 (en) 1998-06-04
PL332074A1 (en) 1999-08-30
AU4128897A (en) 1998-04-02
NO991194D0 (no) 1999-03-11
ZA978133B (en) 1999-04-12
CN1235544A (zh) 1999-11-17
GB9619074D0 (en) 1996-10-23
HUP9904401A3 (en) 2001-03-28
HUP9904401A2 (hu) 2000-06-28
IL128781A0 (en) 2000-01-31
MA24359A1 (fr) 1998-07-01
TR199900505T2 (https=) 1999-06-21
CA2265661A1 (en) 1998-03-19
KR20000036039A (ko) 2000-06-26
BR9711734A (pt) 1999-08-24

Similar Documents

Publication Publication Date Title
US6468560B2 (en) Controlled release dosage form of [R-(Z)]-α-(methoxyimino)-α-(1-azabicyclo[2.2.2]oct-3yl) acetonitrile monohydrochloride
EP0605174B1 (en) Delayed, Sustained-release pharmaceutical preparation
CZ83299A3 (cs) Dávková forma [R-(Z)]-alfa-(methoxyimino)-alfa-(1-azabicyklo[2,2,2]okt-3-yl)acetonitril monohydrochloridu s řízeným uvolňováním
US6749867B2 (en) Delivery system for omeprazole and its salts
CA2521655C (en) Abuse-resistant oral dosage forms and method of use thereof
AU775914B2 (en) Controlled release galantamine composition
JP4535613B2 (ja) 経口モルヒネ多粒子状製剤
EP0567201B1 (en) Vehicles for oral administration of a specific pharmaceutically active acid labile substance
US20030133982A1 (en) Zero-order sustained release dosage forms and method of making same
CZ280797A3 (cs) Vícesložková efervescentní léková forma zahrnující inhibitor protonové pumpy
CA2637444C (en) Coated pharmaceutical composition of tolterodine or a salt thereof having rapid dissolution at acidic conditions and slow dissolution at higher ph values
JP2001526213A (ja) 経口医薬パルス放出剤形
WO2007090882A2 (en) Pharmaceutical extended release compositions comprising pramipexole
WO2011140446A2 (en) Pharmaceutical formulations
WO2003053420A1 (en) Multiple-pulse extended release formulations of clindamycin
WO2009069089A9 (en) Levetiracetam controlled release composition
MXPA99002404A (en) Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2. 2]oct-3-yl)acetonitrile monohydrochloride
CZ20003290A3 (cs) Přípravek
AU2006236052A1 (en) Oral pulsed dose drug delivery system

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic